In order to further understand the biological role of CCL2 expression in a CNS inflammatory disease such as TMEV-IDD, we generated a transgenic mouse line where astrocytes constitutively expressed CCL2 at low levels (Huang et al, 2002) under control of the human glial fibrillary acidic protein (hGFAP) promoter (Brenner et al, 1994) .